345 related articles for article (PubMed ID: 34217681)
1. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
3. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
[TBL] [Abstract][Full Text] [Related]
4. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
[TBL] [Abstract][Full Text] [Related]
5. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
[TBL] [Abstract][Full Text] [Related]
7. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
[TBL] [Abstract][Full Text] [Related]
9. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
Lee CT; Hao W; Burg CA; Best J; Kolenic GE; Strek ME
Respir Res; 2024 Jun; 25(1):255. PubMed ID: 38907239
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
Dempsey TM; Sangaralingham LR; Yao X; Sanghavi D; Shah ND; Limper AH
Am J Respir Crit Care Med; 2019 Jul; 200(2):168-174. PubMed ID: 31150266
[No Abstract] [Full Text] [Related]
11. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
12. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
13. Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Oishi K; Hirano T; Murata Y; Hamada K; Uehara S; Suetake R; Yamaji Y; Asami-Noyama M; Edakuni N; Ohata S; Utsunomiya T; Sakamoto K; Onoda H; Matsumoto T; Matsunaga K; Yano M
Ther Adv Respir Dis; 2019; 13():1753466619872890. PubMed ID: 31476961
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15.
Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
Corral M; DeYoung K; Kong AM
BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
[TBL] [Abstract][Full Text] [Related]
17. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Maher TM; Strek ME
Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
20. Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
Porse S; Hoyer N; Shaker SB
Respir Med; 2022; 204():107015. PubMed ID: 36347111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
